FDA Approves Merck's WELIREG® (belzutifan) for the Treatment of Patients With Advanced Renal Cell Carcinoma (RCC) Following a PD-1 or PD-L1 Inhibitor and a VEGF-TKI -December 14, 2023 at 07:01 pm EST
First and only hypoxia-inducible factor-2 alpha inhibitor approved for these adult patients with advanced RCC This approval of WELIREG marks the first time a new treatment has been approved in a...